{"news_desk": "Business", "print_page": null, "subsection_name": "DealBook", "section_name": "Business Day", "byline": {"original": "By ROBERT CYRAN", "person": [{"firstname": "Robert", "rank": 1, "lastname": "CYRAN", "organization": "", "role": "reported"}]}, "abstract": null, "type_of_material": "News", "word_count": "388", "keywords": [{"rank": "1", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "name": "subject"}, {"rank": "2", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "name": "subject"}, {"rank": "3", "value": "Allergan Inc", "is_major": "N", "name": "organizations"}], "lead_paragraph": "A $2.5 billion purchase of Zeltiq is the drugmaker\u2019s latest bet on growth as it braces for increased competition.", "pub_date": "2017-02-13T20:14:00+0000", "document_type": "article", "source": "The New York Times", "snippet": "A $2.5 billion purchase of Zeltiq is the drugmaker\u2019s latest bet on growth as it braces for increased competition....", "multimedia": [], "web_url": "http://www.nytimes.com/2017/02/13/business/dealbook/allergans-deal-for-fat-freezing-treatment-shows-spending-for-growth.html", "slideshow_credits": null, "blog": [], "_id": "58a2138d7c459f2525d1c20d", "headline": {"main": "Allergan\u2019s Deal for Fat-Freezing Treatment Shows Spending for Growth", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}}